Title Page

Leveraging genetics to improve Body Mass Index increase prediction in the first-episode of psychosis

Gerard Muntané^{1,2,3*}, Javier Vázquez-Bourgon^{2,4*}, Ester Sada^{1,2}, Lourdes Martorell^{1,2}, Sergi Papiol⁵, Elena Bosch^{2,3}, Arcadi Navarro^{3,6,7,8}, Benedicto Crespo-Facorro^{2,9†}, Elisabet Vilella^{1,2‡}.

¹Hospital Universitari Institut Pere Mata, IISPV, Universitat Rovira i Virgili, Reus, Spain.

²Centro de investigación biomédica en red en salud mental (CIBERSAM), Spain.

³Institut de Biologia Evolutiva (UPF-CSIC), Departament de Ciències Experimentals i de la Salut, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain.

⁴Department of Psychiatry, University Hospital Marqués de Valdecilla-Instituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.

⁵Department of Psychiatry, University Hospital, Munich, Germany; Institute of Psychiatric Phenomics and Genomics, University Hospital, Ludwig Maximilian University, Munich, Germany.

⁶Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.

⁷Institució Catalana de Recerca i Estudis Avançats, ICREA, Barcelona, Spain.

⁸Barcelonaβeta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain.

⁹ Department of Psychiatry, University Hospital Virgen del Rocío - Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain

Short running title: Genetics can predict BMI increase in FEP patients

Keywords: BMI increase, polygenic risk scores, pleiotropy, genetics, first-episode psychosis.

* Corresponding authors: Gerard Muntané (muntaneg@peremata.com); Javier Vázquez-Bourgon (javier.vazquez@scsalud.es).

* These authors share senior authorship

Abstract

Background. Individuals with a first episode of psychosis (FEP) show rapid weight gain during the first months of treatment, which is associated with reduction in psychiatric and physical health. Although genetics is assumed to be a significant contributor to this weight gain, its exact role is unknown.

Methods. Reference GWAS from BMI and SCZ were obtained to evaluate the pleiotropic landscape between both traits using the pleioFDR software. In parallel, we gathered a population-based FEP cohort of 381 individuals and BMI Polygenic risk-scores (PRS) were evaluated on a sample of 224 individuals. Subsequently, the PRSs obtained from both BMI and the variants shared between the two traits were incorporated into risk models that included demographic and clinical variable to predict BMI increase (Δ BMI) on an independent sample of 157 patients.

Results. BMI PRS significantly improved the prediction of absolute BMI and Δ BMI during the first 12 months after the onset of psychotic symptoms. This improvement, was mainly explained by shared variants between SCZ and BMI. In contrast, absolute BMI was predicted mainly by non-shared variants.

Conclusions. We validated, for the first time, that genetic factors play a key in the determination of both BMI and Δ BMI in FEP. This finding has important clinical implications in identifying individuals who require specific treatment strategies. Improved risk classification may help prevent associated adverse metabolic events, and reduce overtreatment and costs for both individuals and the healthcare system. It also highlights the importance of studying genetic pleiotropy in the context of medically important comorbidities.

Introduction

Schizophrenia (SCZ) is a severe disorder with a high burden of morbidity and societal impact. It has a heritability of ~80%, much of which is attributable to common risk alleles (1). Patients with SCZ present with a high number of comorbid medical conditions across their lifespan (2,3). In fact, people with SCZ have a higher mortality rate than the general population, corresponding to a 10-20 year reduction in life expectancy, predominantly, due to cardiovascular disease (4,5).

Antipsychotic (AP) drugs can help reduce the intensity and frequency of psychotic symptoms, but on the other hand, they are obesogenic (6). Obesity represents a modifiable risk factor related to adverse health-related outcomes (7), reducing quality of life (8) and adherence to treatment (9). The risk of obesity in patients with SCZ is more than four times higher than in the general population (10). The first year after the initiation of AP treatment is a critical period, in which up to 60-80% of the total weight gain occurs (11,12). Among all factors studied, rapid initial weight gain, AP drug, pre-treatment body mass index (BMI), and sex are the best predictors of weight gain and associated metabolic abnormalities (13–15). However, substantial differences in susceptibility between individuals suggest that weight gain may be partially explained by a mixture of environmental effects and genetic background (16–18). In support of this view, the heritability of weight gain in monozygotic twins has been estimated to be 0.6-0.8 and a few genetic loci have been associated with AP-induced weight gain by genome-wide association studies (GWAS) (19–21). Incidentally, SCZ, given their strong polygenic component, exhibit extensive genetic overlap with other mental disorders (22,23), but also with other non-psychiatric traits (24–26). In particular, studies reported a negative overall genetic correlation between BMI and SCZ, resulting from a mixture of variants with positive and negative effects (26–28).

There is substantial genetic vulnerability to BMI trajectories in the general population (29,30); but it remains to be determined whether the Polygenic Risk Score (PRS) for BMI has any clinical utility in populations with psychiatric disorders. However, the extensive genetic overlap between BMI and SCZ suggests the possibility of developing prediction models including genetic factors. In this study, we aimed to find out whether common genetic variants confer a risk for increased BMI in FEP patients, and to investigate the role of shared variants between SCZ and BMI in such BMI increase (Δ BMI). To our knowledge, this is the first study to demonstrate the importance of genetics in FEP-associated Δ BMI which has the potential to identify individuals at increased risk at the early stages of the disease.

Methods and Materials

Study design

This study includes individuals with a FEP initially enrolled in the Cantabria Program for Early Intervention in Psychosis (PAFIP program, Spain) between 2001 and 2018 (31). Inclusion criteria were: age 16-60 years; living in the catchment area; experiencing their first episode of psychosis (FEP); no prior treatment with AP medication or, if previously treated, a total lifetime of adequate AP treatment of less than 6 weeks. The diagnoses were confirmed using the Structured Clinical Interview for DSM-IV1 (SCID-I) conducted by an experienced psychiatrist at six months from the baseline visit. DSM-IV criteria for drug or alcohol dependence, intellectual disability and having a history of neurological disease or head injury were exclusion criteria. Written informed consent was obtained from all subjects. The Clinical Research Ethics Committee of Cantabria approved the research protocol.

Patients were assigned in 3 consecutive phases of the PAFIP (PAFIP I, II and III), encompassing randomized, flexible-dose, and open-label clinical trials. Patients were randomly assigned to treatment and followed-up for 12 months. During this period, AP doses were adjusted at the

treating psychiatrist's discretion, in an attempt to target the lowest effective dose (32). AP polypharmacy, although not recommended, was allowed if clinically justified. BMI of patients was assessed at baseline (BMI₀) and re-assessed after 3 (BMI₃) and 12 months (BMI₁₂) of treatment initiation. Together with BMI, AP drug prescribed, dose of chlorpromazine equivalents, and whether patients were on antidepressant treatment were collected at every time point. Patients were grouped based on the primary active drug and doses of chlorpromazine equivalents were calculated (33).

Samples and Genotyping

The PAFIP sample was divided into two independent patient datasets. The first dataset including 224 patients was used for discovery (from now on *Training set*), while a second sample including 157 patients was used for replication (from now on *Validation set*). In both datasets, DNA was extracted from peripheral lymphocytes, and genotyping was performed using the Affymetrix 6.0 platform (*Training set*) and the Illumina Infinium PsychArray (*Validation set*), respectively. Standard quality-control procedures (34) were performed with PLINK 1.9 (35), resulting in 6,910,431 SNPs in the *Training set* and 6,552,380 SNPs in the *Validation set* (Supplemental Information). Finally, only those individuals with valid BMI measures were included (Table S1).

Pleiotropy analyses from GWAS data

GWAS summary statistics on BMI were obtained (36), which comprised association analyses of a total of 806,834 European individuals. For SCZ, we obtained GWAS data on 67,390 patients and 94,015 controls, with 80% being of European ancestry (1) (Table S2). GWAS summary statistics were referenced to 9,546,816 SNPs generated from the 1,000 Genomes Project (1KGP, <https://www.internationalgenome.org/>). SNPs that were non-biallelic, without rsIDs, duplicated, or with strand-ambiguous alleles were removed. We also filtered out SNPs with INFO scores ≤ 0.9 , those mapping to the extended major histocompatibility complex (MHC,

chr6: 25,119,106–33,854,733), SNPs located on chromosomes X, Y and mitochondria, and SNPs with sample sizes 5 standard deviations away from the mean. Finally, a common set of 1,949,409 SNPs were kept in both datasets. ORs and betas were transformed into z-scores.

We used *pleioFDR* (<https://github.com/precimed/pleiofdr>) to identify genetic loci jointly associated with the two phenotypes, as previously described (25) (Supplemental information). SNPs jointly associated with BMI and SCZ ($\text{conjFDR} < 0.05$) were mapped to genes with ANNOVAR(37). Genelists were submitted to KOBAS-I (38) to check for enrichment in biological categories and diseases; and to the GENE2FUNC option implemented in FUMA to check for tissue-enrichment (39). All protein-coding genes were used as background and the Benjamini-Hochberg (BH) method was used for false discovery rate (FDR) correction.

To obtain the widest representation of the SNPs in loci shared between SCZ and BMI, SNPs that were in $r^2 > 0.1$, $\text{distance} < 250\text{kb}$, and $\text{MAF} > 0.001$ with each independent SNPs at $\text{conjFDR} < 0.05$ were recovered with PLINK v1.9 from the CEU population of the 1kG project. After this process, all the obtained SNPs were considered as pleiotropic SNPs. Non-pleiotropic SNPs were defined as all the SNPs in the original BMI GWAS that were not contained in any pleiotropic locus.

Polygenic Risk Scores estimation

A Polygenic Risk Score (PRS) is a measure of an individual's genetic load of risk alleles for a certain trait. PRSice 2.3.1.e was used to implement a pipeline in PRS creation (40). The GWAS on BMI (36) was used as base data to calculate PRSs in our sample. We performed P-value-informed clumping with PLINK using a cutoff of $r^2 = 0.1$, 250-kb window, SNPs with $\text{INFO} > 0.9$, and excluding the MHC. Then, we calculated scores for multiple p-thresholds (from $5e-08$ to 1 with increments of $5e-05$).

To calculate PRS we used a two-step procedure as previously developed (41), avoiding sample overlap between the *Training* and *Validation sets* that prevents test statistic inflation. First,

PRSs were calibrated in the *Training set* and the optimal p-value (P_{optimal}) threshold was determined as the one with the highest prediction for each phenotype (BMI and ΔBMI at baseline, 3, and 12 months). Sex, age and the 10 first PCs were included as covariates (when evaluating ΔBMIs , BMI_0 was also included as covariate). Then, SNPs that fell below each obtained P_{optimal} threshold were identified and carried forward for PRS computation in individuals of the *Validation set*.

Statistical Analyses

To elucidate which variables were associated with BMI and ΔBMI in our dataset we carried out multiple linear regression followed by type II ANOVA, to test the improvement in the predictive ability of the PRS inclusion. The linear models included the 10 first PCs (to adjust for population stratification), sex, age, AP dose and the type of AP drug (at 3 and 12 months), the diagnosis, and use of antidepressants. Whenever necessary, ΔBMI_3 and BMI_0 were also included. These models combining only clinical and demographic variables were referred to as *Null models*. Then, to examine the predictive ability of BMI PRS, we created a series of absolute risk models including genetic factors, that consisted of multiple linear regression analyses with the observed BMI (or ΔBMI) as the dependent variable and the covariates in the *Null model* plus the P_{optimal} PRS, named as *PRS models*. To decipher the role of variants jointly associated with BMI and SCZ, we independently evaluated the *PRS models* using PRS derived from both pleiotropic and non-pleiotropic loci. In those cases, only SNPs from each category were included. Finally, Kruskal-Wallis test was used to compare whether the AP drug prescribed affected ΔBMI at 3 months (ΔBMI_3) and ΔBMI at 12 months (ΔBMI_{12}). All the analyses were performed in R 3.6.0 (42).

Results

Characteristics of the sample

A total of 381 patients were included. Among them, 188 (49.3%) were diagnosed with schizophrenia, 115 (30.2%) with schizophreniform disorder, 43 (11.3%) with brief psychotic disorder, 28 (7.4%) with unspecified psychosis, 5 (1.3%) with schizoaffective disorder, and 2 (0.5%) with delusional disorder. At the end of the study, 89.2% of the patients had all BMI measures (Table S1). None of the participants was initially treated with clozapine, which is indicated in treatment-resistant SCZ (43) (Table 1).

In the whole dataset, the mean ΔBMI_3 and ΔBMI_{12} were 6.4% and 13.9%, respectively (Figure S1). Most of the individuals displayed a positive ΔBMI_{12} ($n=312$, 91.8%), 25 individuals (7.4%) showed a negative ΔBMI_{12} , and 3 individuals ($<0.1\%$) presented the same BMI_0 and BMI_{12} . In total, 108 patients in the *Training set* (48.2%) and 94 in the *Validation set* (59.9%) remained with the same AP drug during the study (Figure S2). Both ΔBMI_3 and ΔBMI_{12} were negatively correlated with BMI_0 ($P=5.56\text{e-}10$ and $P=7.07\text{e-}07$) and positively correlated among them (Figure S3). All APs were associated, on average, with a positive ΔBMI (Figure S4 and Supplemental Information).

Pleiotropy between SCZ and BMI

A total of 486 independent SNPs belonging to 449 near-independent genomic loci ($r^2 \leq 0.1$) were identified to be jointly associated with SCZ and BMI at $\text{conjFDR} \leq 0.05$ (Figure 1A and Table S3). Among them, 169 independent SNPs (35%) showed agonistic relationships between SCZ and BMI, where the alleles that confer risk for SCZ, also increase BMI. In addition, 317 independent SNPs (65%) showed antagonistic links, where the allele that increased SCZ-risk, had a BMI reduction effect (Figure 1B). This represented an approximate two-fold ratio between negative (antagonistic) and positive (agonistic) pleiotropic variants (Figure S5). Both groups of variants did not differ in their effects in SCZ ($P=0.45$) or BMI ($P=0.17$), nor in their minor allele frequency ($P=0.72$).

The whole set of SNPs shared between SCZ and BMI included 9,262 SNPs corresponding to 889 genes in total, which were enriched in DNA methylation (FDR=4,99e-14), DNA damage (FDR=7,52e-13), cAMP signaling pathway (FDR=2,45e-09), axon guidance (FDR=1,06e-07), dopaminergic synapse (FDR=2,99e-05), insulin resistance (FDR=6,57e-03), and nervous system diseases (FDR=7,58e-05), among others (Table S4; Figure S6). These genes were differentially regulated in the brain; especially being up-regulated in the frontal cortex, anterior cingulate cortex, putamen, amygdala, nucleus accumbens, and hippocampus (Figure S7). A complete list of pathways enriched in agonistic and antagonistic loci can be found in Tables S5 and S6.

Risk models for BMI and Δ BMI

Among the included variables in the *Null models* in the whole dataset, BMI₀ contributed the most with 8.7% of the variance in Δ BMI₃, AP treatment contributed 7.5% and sex 1.5%. BMI₀ contributed 4.3% to the total variance of Δ BMI₁₂, AP treatment 6.4%, and age 2.7% (Supplemental Information). If Δ BMI₃ was included, it drastically improved the model for Δ BMI₁₂, accounting for 28.6% of its variance (Figure 2).

PRS were calculated for BMI₀, BMI₃, and BMI₁₂, the P_{optimal} in the *Training set* were established at 0.15, 0.15, and 0.08, respectively (Table S7). The *PRS models* showed an adjusted R^2 ($\text{Adj}R^2$) of 0.11 for BMI₀ ($P=0.01$), 0.13 for BMI₃ ($P=0.01$), and 0.21 for BMI₁₂ ($P=2.4\text{e-}03$) in the *Validation set* (Table S8). In summary, the inclusion of PRS improved the *Null models* by 40% for BMI₀, 32% for BMI₃, and 55.5% for BMI₁₂ (Figure 3). Next, we investigated the inclusion of PRS in predicting Δ BMI₃ and Δ BMI₁₂. The P_{optimal} thresholds in the *Training set* were estimated at $2.2\text{e-}03$ and 0.01, for Δ BMI₃ and Δ BMI₁₂, respectively (Table S7). The *PRS models* showed $\text{Adj}R^2$ of 0.19 for Δ BMI₃ ($P=1.3\text{e-}03$) and 0.10 for Δ BMI₁₂ ($P=0.04$, Table S9). The inclusion of PRS ostensibly improved the *Null models* by 50.7% in Δ BMI₁₂ ($P=0.02$), but not Δ BMI₃ ($P=0.35$). BMI₀ is in part explained by the BMI PRS, so we decided to exclude it from the models. In this

case, *PRS models* improved the *Null models* of both ΔBMI_{12} (177.3%, $P=8.3\text{e-}03$), and ΔBMI_3 (21.2%, $P=0.03$, Figure 4).

Next, we wanted to investigate whether loci shared between SCZ and BMI played any role in BMI and ΔBMI . So, we divided the genome-wide significant SNPs ($P<5\text{e-}08$) from BMI GWAS into pleiotropic and non-pleiotropic, using information from the conjunctive analysis, to obtain two BMI PRS based on pleiotropic and non-pleiotropic SNPs (Figure S8). The pleiotropic variants between SCZ and BMI (Table S10) played no role in determining BMI at any time ($P=0.58$, $P=0.80$, and $P=0.58$ for BMI_0 , BMI_3 , and BMI_{12} , respectively), while variants coming from non-pleiotropic loci improved prediction in a similar way as all SNPs: by 44% for BMI_0 ($P=0.01$), 40.2% for BMI_3 ($P=0.01$), and by 68.2% for BMI_{12} ($P=4.3\text{e-}04$, Figure 3). In contrast, when evaluating ΔBMI , the *PRS model* obtained from the pleiotropic regions improved the ΔBMI_3 model by a 12.7% ($P=0.03$) and the ΔBMI_{12} model by 60.9% ($P=0.01$, Figure 4). PRS obtained from non-pleiotropic regions was not relevant for predicting ΔBMI_3 ($P=0.25$); however, it also significantly improved the *Null model* for ΔBMI_{12} by 55.1% ($P=0.02$). Finally, when the PRS was derived only from antagonistic loci, the risk models for both ΔBMIs outperformed the ones obtained with agonistic loci, being similar to those obtained with the inclusion of pleiotropic PRS (Figure S9).

If BMI_0 was not considered in the models, inclusion of PRS from the pleiotropic loci increased by 21.6% ($P=0.03$) the ΔBMI_3 model, and by 175.9% the ΔBMI_{12} ($P=8.3\text{e-}03$, Figure 4C). In contrast, non-pleiotropic loci did not improve any of the *Null models* without BMI_0 ($P=0.76$ and $P=0.1$ for ΔBMI_3 and ΔBMI_{12} , respectively).

Discussion

Understanding the genetic vulnerability associated with increased BMI carries the potential to predict its risk prior to treatment initiation and implement personalized risk-based treatments.

In this study, we demonstrate for the first time, the replicable effects of BMI PRS in predicting Δ BMI in FEP.

In our study, BMI₀ was inversely associated with Δ BMI₃ and Δ BMI₁₂, indicating that individuals with lower BMI₀ were more likely to have higher Δ BMI during the first year of treatment (44). Remarkably, Δ BMI₁₂ was strongly predicted by Δ BMI₃ (explaining 30% of its variance), underscoring the importance of the first weeks of treatment on the outcome of obesity associated with psychosis, emphasizing the idea that clinicians should put the focus on early weeks to prevent long-term weight gain (45). In the analyses of patients who did not switch AP, our results are in accordance with previous studies in which a greater gain is observed in patients treated with atypical AP (46,47). However, the effects varied greatly within medications and interactions with underlying individual characteristics and genetic factors become relevant(48).

We confirm and extend with further data the shared genetic architecture between BMI and SCZ, involving pathways such as DNA damage, DNA methylation, insulin resistance, and dopaminergic and glutamatergic synapses in weight gain (26). These molecular pathways become promising mechanisms for understanding weight gain in FEP. Specific DNA methylation signatures have been widely described to play a role in obesity and weight loss in humans (49–51). There is also evidence pointing to the relevance of the glutamatergic system as a promising strategy to treat obesity (52). Also, weight gain associated with clozapine may be linked to antagonism of the histaminergic H1 receptors, increasing the risk for insulin resistance and type 2 diabetes (53).

Here, we demonstrate the role of genetics underlying both BMI and Δ BMI in FEP patients. The inclusion of the BMI PRS ostensibly improved the absolute BMI prediction. This is not surprising, as the role of genetics in BMI in the general population is already known (29), yet this is the first time it is also validated in FEP individuals. Notably, the inclusion of BMI genetic

scores also improved the prediction of medium term ΔBMI . And strikingly, the inclusion of the PRS of pleiotropic regions between SCZ and BMI improved the risk model of ΔBMI_{12} and ΔBMI_3 . This observation was made stronger when BMI_0 was not accounted for in the models. Our results also indicate a greater role for antagonistic variants in predicting ΔBMI . However, it could be simply a matter of statistical power as more SNPs were recovered in this category. In contrast, the genetic architecture of BMI not shared with SCZ played a pivotal role in controlling BMI. All these results highlight the importance of including patient genetic information to improve the prediction of weight gain in FEP patients.

Our study has one main strength; it is based on two independent longitudinal and prospective cohorts of well-characterized drug-naïve FEP patients. However, our work has some limitations; first, we could not control for well-known factors that contribute to BMI changes, such as diet and physical activity (54,55). Secondly, the interpretation of the results could also be skewed by the fact that FEP patients often switch AP treatment during follow-up, and are sometimes treated with a secondary AP and other psychiatric medications, all of them with a possible impact on BMI (56). Moreover, there may have been unrecorded extra changes in the AP prescriptions between the study timepoints. We have tried to reduce this problem by including current and past AP treatment in the models. Noteworthy, the two cohorts do not have the same distributions of AP treatments. Although this may imply a bias when comparing results between AP drugs, it also reinforces the role of genetics in ΔBMI given its replicability even in sets of individuals with different treatments. Future research with larger cohorts and including populations of non-European ancestry could provide even more information on genetic vulnerability to ΔBMI .

In summary, our findings highlight that genetics is an important factor in determining weight gain in patients with FEP, suggesting its inclusion in the clinical routine to identify individuals at higher risk, and to optimize individualized prevention programs and management to improve

their quality of life. In turn, our findings pave the way to address the prediction of comorbid trajectories in other diseases using a similar approach.

Acknowledgements

This work was supported by the Catalan Agency of Research and Universities (AGAUR, 2017SGR-00444, PI: EV). GM is supported by Instituto de Salud Carlos III (PI18/00514 and PI21/00612). The Santander (PAFIP) cohort was funded by the following grants: Instituto de Salud Carlos III (FIS00/3095, PI020499, PI050427, PI060507), Plan Nacional de Drogas Research (2005-Orden sco/3246/2004), SENY Fundatio Research (2005-0308007), Fundacion Marques de Valdecilla (A/02/07, API07/011) and MINECO/FEDER (SAF2016-76046-R, SAF2013-46292-R). JV-B is supported by funding from Instituto de Investigación Valdecilla (INT/A21/10, INT/A20/04). AN is supported by funding from AEI-PGC2018-BI00 (FEDER/UE)(MINECO/FEDER, UE), “Unidad de Excelencia María de Maeztu”, funded by the AEI (CEX2018-000792-M), Secretaria d’Universitats i Recerca and CERCA Programme of the Departament d’Economia i Coneixement de la Generalitat de Catalunya (GRC 2017 SGR 880).

Conflicts of Interest

BC-F has received honoraria (advisory board and educational lectures) and travel expenses from Takeda, Menarini, Angelini, Teva, Otsuka, Lundbeck, and Johnson & Johnson. He has also received unrestricted research grants from Lundbeck. JV-B has received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen-Cilag and Lundbeck. The rest of authors report no biomedical financial interests or potential conflicts of interest.

References

1. Schizophrenia Working Group of the Psychiatric Genomics Consortium, Ripke S, Walters JT, O'Donovan MC. *Mapping Genomic Loci Prioritises Genes and Implicates Synaptic Biology in Schizophrenia*. Genetic and Genomic Medicine; 2020.
doi:10.1101/2020.09.12.20192922
2. Krebs MD, Themudo GE, Benros ME, et al. Associations between patterns in comorbid diagnostic trajectories of individuals with schizophrenia and etiological factors. *Nat Commun*. 2021;12(1):6617. doi:10.1038/s41467-021-26903-7
3. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis. *Schizophr Bull*. 2013;39(2):306-318.
doi:10.1093/schbul/sbr148
4. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. *Annu Rev Clin Psychol*. 2014;10:425-448. doi:10.1146/annurev-clinpsy-032813-153657
5. Kurdyak P, Mallia E, de Oliveira C, et al. Mortality After the First Diagnosis of Schizophrenia-Spectrum Disorders: A Population-based Retrospective Cohort Study. *Schizophr Bull*. 2021;47(3):864-874. doi:10.1093/schbul/sbaa180
6. Rødevand L, Steen NE, Elvsåshagen T, et al. Cardiovascular risk remains high in schizophrenia with modest improvements in bipolar disorder during past decade. *Acta Psychiatr Scand*. 2019;139(4):348-360. doi:10.1111/acps.13008
7. Vázquez-Bourgon J, Ibáñez Alario M, Mayoral-van Son J, et al. A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients. *Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol*. 2020;39:46-55. doi:10.1016/j.euroneuro.2020.08.009
8. McWhinney S, Kolenic M, Franke K, et al. Obesity as a Risk Factor for Accelerated Brain Ageing in First-Episode Psychosis—A Longitudinal Study. *Schizophr Bull*. Published online

June 3, 2021:sbab064. doi:10.1093/schbul/sbab064

9. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. *Psychiatr Serv Wash DC*. 2003;54(4):565-567.
doi:10.1176/appi.ps.54.4.565
10. Müller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. *Pharmacogenomics*. 2006;7(6):863-887. doi:10.2217/14622416.7.6.863
11. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. *World Psychiatry*. 2015;14(2):119-136.
doi:10.1002/wps.20204
12. Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *The Lancet*. 2009;373(9669):1083-1096. doi:10.1016/S0140-6736(09)60318-4
13. Pérez-Iglesias R, Martínez-García O, Pardo-García G, et al. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors. *Int J Neuropsychopharmacol*. 2014;17(1):41-51. doi:10.1017/S1461145713001053
14. Bioque M, García-Portilla M a P, García-Rizo C, et al. Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. *Schizophr Res*. 2018;193:188-196. doi:10.1016/j.schres.2017.06.032
15. Gebhardt S, Haberhausen M, Heinzl-Gutenbrunner M, et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. *J Psychiatr Res*. 2009;43(6):620-626. doi:10.1016/j.jpsychires.2008.11.001
16. Vázquez-Bourgon J, Mayoral-van Son J, Gómez-Revuelta M, et al. Treatment Discontinuation Impact on Long-Term (10-Year) Weight Gain and Lipid Metabolism in First-Episode Psychosis: Results From the PAFIP-10 Cohort. *Int J Neuropsychopharmacol*.

2021;24(1):1-7. doi:10.1093/ijnp/pyaa066

17. Álvarez-Jiménez M, González-Blanch C, Crespo-Facorro B, et al. Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic Disorders: A Systematic Critical Reappraisal. *CNS Drugs*. 2008;22(7):547-562. doi:10.2165/00023210-200822070-00002
18. Raben AT, Marshe VS, Chintoh A, Gorbovskaia I, Müller DJ, Hahn MK. The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment. *Front Neurosci*. 2017;11:741. doi:10.3389/fnins.2017.00741
19. Theisen FM, Gebhardt S, Haberhausen M, et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. *Psychiatr Genet*. 2005;15(4):285-289. doi:10.1097/00041444-200512000-00011
20. Tiwari HK, Patki A, Lieberman J, et al. Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study). *Front Genet*. 2011;2. doi:10.3389/fgene.2011.00056
21. Gebhardt S, Theisen FM, Haberhausen M, et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study: *Twin/sib study on antipsychotic-induced weight gain*. *J Clin Pharm Ther*. 2010;35(2):207-211. doi:10.1111/j.1365-2710.2009.01084.x
22. Ter Hark SE, Jamain S, Schijven D, et al. A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort). *J Psychopharmacol Oxf Engl*. 2020;34(5):524-531. doi:10.1177/0269881120907972
23. Maciukiewicz M, Tiwari AK, Zai CC, et al. Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans. *Schizophr Res*. 2019;212:204-212. doi:10.1016/j.schres.2019.07.022
24. Lee PH, Anttila V, Won H, et al. Genomic Relationships, Novel Loci, and Pleiotropic

- Mechanisms across Eight Psychiatric Disorders. *Cell*. 2019;179(7):1469-1482.e11.
doi:10.1016/j.cell.2019.11.020
25. Andreassen OA, Djurovic S, Thompson WK, et al. Improved Detection of Common Variants Associated with Schizophrenia by Leveraging Pleiotropy with Cardiovascular-Disease Risk Factors. *Am J Hum Genet*. 2013;92(2):197-209.
doi:10.1016/j.ajhg.2013.01.001
 26. Smeland OB, Bahrami S, Frei O, et al. Genome-wide analysis reveals extensive genetic overlap between schizophrenia, bipolar disorder, and intelligence. *Mol Psychiatry*. 2020;25(4):844-853. doi:10.1038/s41380-018-0332-x
 27. Muntané G, Farré X, Bosch E, Martorell L, Navarro A, Vilella E. The shared genetic architecture of schizophrenia, bipolar disorder and lifespan. *Hum Genet*. Published online August 9, 2020. doi:10.1007/s00439-020-02213-8
 28. Bahrami S, Steen NE, Shadrin A, et al. Shared Genetic Loci Between Body Mass Index and Major Psychiatric Disorders: A Genome-wide Association Study. *JAMA Psychiatry*. 2020;77(5):503-512. doi:10.1001/jamapsychiatry.2019.4188
 29. Duncan LE, Shen H, Ballon JS, Hardy KV, Noordsy DL, Levinson DF. Genetic Correlation Profile of Schizophrenia Mirrors Epidemiological Results and Suggests Link Between Polygenic and Rare Variant (22q11.2) Cases of Schizophrenia. *Schizophr Bull*. 2018;44(6):1350-1361. doi:10.1093/schbul/sbx174
 30. Ikeda M, Tanaka S, Saito T, Ozaki N, Kamatani Y, Iwata N. Re-evaluating classical body type theories: genetic correlation between psychiatric disorders and body mass index. *Psychol Med*. 2018;48(10):1745-1748. doi:10.1017/S0033291718000685
 31. Khera AV, Chaffin M, Wade KH, et al. Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. *Cell*. 2019;177(3):587-596.e9.
doi:10.1016/j.cell.2019.03.028
 32. Krapohl E, Patel H, Newhouse S, et al. Multi-polygenic score approach to trait prediction.

- Mol Psychiatry*. 2018;23(5):1368-1374. doi:10.1038/mp.2017.163
33. Peters T, Nüllig L, Antel J, et al. The Role of Genetic Variation of BMI, Body Composition, and Fat Distribution for Mental Traits and Disorders: A Look-Up and Mendelian Randomization Study. *Front Genet*. 2020;11:373. doi:10.3389/fgene.2020.00373
 34. Pelayo-Terán JM, Pérez-Iglesias R, Ramírez-Bonilla M, et al. Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. *Early Interv Psychiatry*. 2008;2(3):178-187. doi:10.1111/j.1751-7893.2008.00074.x
 35. Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, et al. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. *Int J Neuropsychopharmacol*. 2020;23(4):217-229. doi:10.1093/ijnp/pyaa004
 36. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ. International Consensus Study of Antipsychotic Dosing. *Am J Psychiatry*. 2010;167(6):686-693. doi:10.1176/appi.ajp.2009.09060802
 37. Marees AT, de Kluiver H, Stringer S, et al. A tutorial on conducting genome-wide association studies: Quality control and statistical analysis. *Int J Methods Psychiatr Res*. 2018;27(2):e1608. doi:10.1002/mpr.1608
 38. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007;81(3):559-575. doi:10.1086/519795
 39. Pulit SL, Stoneman C, Morris AP, et al. Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry. *Hum Mol Genet*. 2019;28(1):166-174. doi:10.1093/hmg/ddy327
 40. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res*. 2010;38(16):e164-e164.

doi:10.1093/nar/gkq603

41. Bu D, Luo H, Huo P, et al. KOBAS-i: intelligent prioritization and exploratory visualization of biological functions for gene enrichment analysis. *Nucleic Acids Res.* 2021;49(W1):W317-W325. doi:10.1093/nar/gkab447
42. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun.* 2017;8(1):1826. doi:10.1038/s41467-017-01261-5
43. Choi SW, O'Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data. *GigaScience.* 2019;8(7). doi:10.1093/gigascience/giz082
44. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet.* 2018;50(9):1219-1224. doi:10.1038/s41588-018-0183-z
45. R Core Team. *R: A Language and Environment for Statistical Computing.* R Foundation for Statistical Computing; 2021. <https://www.R-project.org/>
46. Kane JM, Agid O, Baldwin ML, et al. Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. *J Clin Psychiatry.* 2019;80(2):18com12123. doi:10.4088/JCP.18com12123
47. Manu P, Dima L, Shulman M, Vancampfort D, De Hert M, Correll CU. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. *Acta Psychiatr Scand.* 2015;132(2):97-108. doi:10.1111/acps.12445
48. Harrison RNS, Gaughran F, Murray RM, et al. Development of multivariable models to predict change in Body Mass Index within a clinical trial population of psychotic individuals. *Sci Rep.* 2017;7(1):14738. doi:10.1038/s41598-017-15137-7
49. Malhotra R, Ostbye T, Riley CM, Finkelstein EA. Young adult weight trajectories through midlife by body mass category. *Obes Silver Spring Md.* 2013;21(9):1923-1934. doi:10.1002/oby.20318

50. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association Between Early and Rapid Weight Gain and Change in Weight Over One Year of Olanzapine Therapy in Patients with Schizophrenia and Related Disorders. *J Clin Psychopharmacol*. 2005;25(3):255-258. doi:10.1097/01.jcp.0000161501.65890.22
51. Hugenholtz GW, Heerdink ER, Meijer WE, Stolker JJ, Egberts AC, Nolen WA. Reasons for switching between antipsychotics in daily clinical practice. *Pharmacopsychiatry*. 2005;38(3):122-124. doi:10.1055/s-2005-864122
52. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. *Am J Psychiatry*. 2003;160(8):1396-1404. doi:10.1176/appi.ajp.160.8.1396
53. Lett TAP, Wallace TJM, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. *Mol Psychiatry*. 2012;17(3):242-266. doi:10.1038/mp.2011.109
54. Dick KJ, Nelson CP, Tsaprouni L, et al. DNA methylation and body-mass index: a genome-wide analysis. *The Lancet*. 2014;383(9933):1990-1998. doi:10.1016/S0140-6736(13)62674-4
55. Samblas M, Milagro FI, Martínez A. DNA methylation markers in obesity, metabolic syndrome, and weight loss. *Epigenetics*. 2019;14(5):421-444. doi:10.1080/15592294.2019.1595297
56. Tobi EW, Slieker RC, Luijk R, et al. DNA methylation as a mediator of the association between prenatal adversity and risk factors for metabolic disease in adulthood. *Sci Adv*. 2018;4(1):eaao4364. doi:10.1126/sciadv.aao4364
57. Oliveira TPD, Gonçalves BDC, Oliveira BS, et al. Negative Modulation of the Metabotropic Glutamate Receptor Type 5 as a Potential Therapeutic Strategy in Obesity and Binge-Like Eating Behavior. *Front Neurosci*. 2021;15:631311. doi:10.3389/fnins.2021.631311

58. Guest PC. Insulin Resistance in Schizophrenia. In: Guest PC, ed. *Reviews on Biomarker Studies of Metabolic and Metabolism-Related Disorders*. Vol 1134. Advances in Experimental Medicine and Biology. Springer International Publishing; 2019:1-16.
doi:10.1007/978-3-030-12668-1_1
59. Tomasik J, Lago SG, Vázquez-Bourgon J, et al. Association of Insulin Resistance With Schizophrenia Polygenic Risk Score and Response to Antipsychotic Treatment. *JAMA Psychiatry*. 2019;76(8):864. doi:10.1001/jamapsychiatry.2019.0304
60. Firth J, Stubbs B, Teasdale SB, et al. Diet as a hot topic in psychiatry: a population-scale study of nutritional intake and inflammatory potential in severe mental illness. *World Psychiatry*. 2018;17(3):365-367. doi:10.1002/wps.20571
61. Vancampfort D, Firth J, Schuch FB, et al. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis. *World Psychiatry*. 2017;16(3):308-315.
doi:10.1002/wps.20458
62. Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. *Schizophr Bull*. 2009;35(2):443-457. doi:10.1093/schbul/sbn018

Figure Legends

Figure 1. Pleiotropic variants between SCZ and BMI. A) Manhattan plot showing independent ($r^2 \leq 0.1$) loci associated with both SCZ and BMI, as defined by conjunction false discovery rates (conjFDR) after excluding SNPs in the MHC region. The dashed black line represents the conjFDR threshold of 0.05. B) Pleiotropy plot for independent SNPs with conjFDR ≤ 0.05 ($n = 486$) between SCZ and BMI. The conjFDR values and the direction of the effects (z-scores) of the minor alleles are plotted for BMI (x-axis) against SCZ (y-axis). Graph regions whose effects are consistent with a positive correlation between both traits are shadowed in yellow. C) Ratio between negative and positive pleiotropic variants across different conjFDR thresholds.

Figure 2. Δ BMI variance explained. Bar plots showing the variance explained by each covariate in the *Null models* for A) Δ BMI₃, B) Δ BMI₁₂, and C) Δ BMI₁₂ including Δ BMI₃ in the model. In the plots the variables for medication (either AP and CPZ) at 3m and 12m were merged. AP: Antipsychotic drug; CPZ: equivalent doses of chlorpromazine. *P value ≤ 0.05 ; **P value ≤ 0.01 ; ***P value < 0.001 .

Figure 3. *Null* vs *PRS* models in BMI. Barplots showing the AdjR² in BMI by the *Null model* and the *PRS model* computed using all SNPs (PRS), pleiotropic SNPs (PLEIO), and non-pleiotropic SNPs (NOPLEIO) from BMI GWAS. The barplot shows predictions of BMI₀, BMI₃ and BMI₁₂, in the x-axis. Covariates included in the *Null model* were the first 10 PC, age, sex, AP drug prescribed, chlorpromazine equivalent doses, diagnose, and the presence or not of antidepressant treatment. Asterisks represent significantly improved models compared to the *Null models* (anova). *P value ≤ 0.05 ; **P value ≤ 0.01 ; ***P value < 0.001 .

Figure 4. Null vs PRS models in Δ BMI. Barplots showing the AdjR² (y-axis) in Δ BMI by the *Null model* (red), and *PRS model* computed using all SNPs (PRS), only pleiotropic SNPs (PLEIO), and non-pleiotropic SNPs (NOPLEIO) in the *Validation dataset* (n=157). A) Multiple linear models including BMI₀ as a covariate in the model. B) Multiple linear models excluding BMI₀ from the list of covariates. The rest of covariates included in the *Null model* were the 10 first PCs, AP treatment, chlorpromazine equivalent doses, age, sex, SSD diagnose, and being treated with antidepressant. Asterisks represent significantly improved *PRS models* compared to the *Null models* (anova).

·P value < 0.1; *P value < 0.05; **P value < 0.01; ***P value < 0.001.

Tables

Table 1. Number of participants in each treatment category at baseline and after 3 and 12 months of follow-up.

<i>drug</i>	<i>t=0</i>		<i>t=3months</i>		<i>t=12 months</i>	
	<i>Training</i>	<i>Validation</i>	<i>Training</i>	<i>Validation</i>	<i>Training</i>	<i>Validation</i>
Aripiprazole	101 (45.1%)	11 (7%)	81 (38%)	9 (5.8%)	81 (38.6%)	9 (6.3%)
Clozapine	-	-	3 (1.4%)	-	10 (4.8%)	2 (1.4%)
Trifluoperazine	-	-	1 (0.5%)	-	-	-
Haloperidol	-	34 (21.7%)	-	31 (20.1%)	-	17 (11.9%)
Olanzapine	1 (0.4%)	42 (26.8%)	13 (6.1%)	45 (29.2%)	24 (11.4%)	46 (32.2%)
Paliperidone	-	-	3 (1.4%)	-	12 (5.7%)	-
Quetiapine	34 (21.7%)	15 (9.6%)	14 (6.6%)	12 (7.8%)	13 (6.2%)	18 (12.6%)
Risperidone	49 (21.9%)	43 (27.4%)	71 (33.3%)	49 (31.8%)	54 (25.7%)	44 (30.8%)
Ziprasidone	39 (24.8%)	12 (7.6%)	27 (12.7%)	8 (5.2%)	15 (7.1%)	7 (4.9%)
Amisulpride	-	-	-	-	1 (0.5%)	-
TOTAL	224	157	213	154	210	143

A

B

Figure 1

Figure 2

Figure 3

A

B

Figure 4